Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines

被引：58
作者：
Dogan, AL
Legrand, O
Faussat, AM
Perrot, JY
Marie, JP
机构：
[1] Univ Paris 06, Hop Hotel Dieu AP HP, Dept Oncohematol, INSERM,Lab E03 55,EA 1529, F-75004 Paris, France
[2] Hacettepe Univ, Inst Oncol, Dept Basic Oncol, Ankara, Turkey
来源：
LEUKEMIA RESEARCH | 2004年 / 28卷 / 06期
关键词：
MRP1; MDR1 carboxyfluorescein diacetate (CFDA); calcein-AM; rhodamine 123 (Rh123);
D O I：
10.1016/j.leukres.2003.10.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MRP1 activity was evaluated and compared in 11 cell lines with different levels of MRP1 expression using functional assays of calcein acetoxymethyl ester (calcein-AM), carboxyfluorescein diacetate (CFDA) and Rhodamine 123 (Rh123) in combination with the modulators cyclosporin A (CsA), probenecid and MK571. A good correlation was found between MRP1 expression and the modulatory effect of MK571 on calcein-AM uptake (P = 0.01) and probenecid effect on CFDA uptake (P = 0.02). Additionally, the combined modulatory effect of MK571 and probenecid on CFDA uptake (P < 0.0001) and on calcein-AM uptake (P = 0.0001) were highly significant. No correlation was found between MRP1 expression and the effects of three modulators on Rh123 uptake or efflux. In conclusion, calcein-AM and CFDA uptake assays are the best choices to probe MRP1 activity and combination of two modulators may improve the efficiency of these assays. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码：619 / 622
页数：4
相关论文
共 11 条
[1]   Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia [J].
Broxterman, HJ ;
Lankelma, J ;
Pinedo, HM ;
Eekman, CA ;
Wahrer, DCR ;
Ossenkoppele, GJ ;
Schuurhuis, GJ .
LEUKEMIA, 1997, 11 (07) :1110-1118
[2]   Kinetic analysis of calcein and calcein -: Acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein [J].
Essodaïgui, M ;
Broxterman, HJ ;
Garnier-Suillerot, A .
BIOCHEMISTRY, 1998, 37 (08) :2243-2250
[3]   THE LEUKOTRIENE LTD(4) RECEPTOR ANTAGONIST MK571 SPECIFICALLY MODULATES MRP ASSOCIATED MULTIDRUG-RESISTANCE [J].
GEKELER, V ;
ISE, W ;
SANDERS, KH ;
ULRICH, WR ;
BECK, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 208 (01) :345-352
[4]   High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival [J].
Laupeze, B ;
Amiot, L ;
Drenou, B ;
Bernard, M ;
Branger, B ;
Grosset, JM ;
Lamy, T ;
Fauchet, R ;
Fardel, O .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (04) :834-838
[5]   Role of MRP1 in multidrug resistance in acute myeloid leukemia [J].
Legrand, O ;
Zittoun, R ;
Marie, JP .
LEUKEMIA, 1999, 13 (04) :578-584
[6]   Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients [J].
Legrand, O ;
Simonin, G ;
Perrot, JY ;
Zittoun, R ;
Marie, JP .
BLOOD, 1998, 91 (12) :4480-4488
[7]   Multicentric evaluation of the MDR phenotype in leukemia [J].
Marie, JP ;
Huet, S ;
Faussat, AM ;
Perrot, JY ;
Chevillard, S ;
Barbu, V ;
Bayle, C ;
Boutonnat, J ;
Calvo, F ;
CamposGuyotat, L ;
Colosetti, P ;
Cazin, JL ;
deCremoux, P ;
Delvincourt, C ;
Demur, C ;
Drenou, B ;
Fenneteau, O ;
Feuillard, J ;
GarnierSuillerot, A ;
Genne, P ;
Gorisse, MC ;
Gosselin, P ;
Jouault, H ;
Lacave, R ;
LeCalvez, G ;
Leglise, MC ;
Leonce, S ;
Manfait, M ;
Maynadie, M ;
MerleBeral, H ;
Merlin, JL ;
Mousseau, M ;
Morjani, H ;
Picard, F ;
Pinguet, F ;
Poncelet, P ;
Racadot, E ;
Raphael, M ;
Richard, B ;
Rossi, JF ;
Schlegel, N ;
Vielh, P ;
Zhou, DC ;
Robert, J .
LEUKEMIA, 1997, 11 (07) :1086-1094
[8]   Novel mechanisms of drug resistance in leukemia [J].
Ross, DD .
LEUKEMIA, 2000, 14 (03) :467-473
[9]  
van der Kolk DM, 1998, CLIN CANCER RES, V4, P1727
[10]   Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia [J].
van der Kolk, DM ;
de Vries, EGE ;
Noordhoek, L ;
van den Berg, E ;
van der Pol, MA ;
Müller, M ;
Vellenga, E .
LEUKEMIA, 2001, 15 (10) :1544-1553
12